文献速递甲状腺疾病

老年甲状腺癌患者的竞争性死亡原因分析

Competing Causes of Death in Older Adults with Thyroid Cancer.
PubMed 文献 · Thyroid · 2021-04-21

该研究基于SEER-Medicare数据库,纳入2000至2015年确诊的21509例≥66岁甲状腺癌患者,中位随访50个月。结果显示19.4%死于其他原因,12.3%死于甲状腺癌;分化型甲状腺癌患者死于其他原因的可能性超过死于甲状腺癌,而未分化癌则相反。特定合并症与死于其他原因相关,肿瘤特征与死于甲状腺癌相关。

要点

  • 老年分化型甲状腺癌患者死于其他原因的风险高于死于甲状腺癌。
  • 未分化甲状腺癌患者死于甲状腺癌的风险更高,髓样癌6.25年后其他原因死亡风险更高。
  • 男性、黑人种族及合并症(如心脏病)与死于其他原因相关。

核心结论

  • 老年甲状腺癌患者中,分化型甲状腺癌死于其他原因的可能性超过死于甲状腺癌,而未分化癌则相反。
  • 临床管理应综合考虑患者具体合并症等临床背景。

研究设计与样本

  • 基于SEER-Medicare数据库的回顾性队列研究,纳入2000至2015年确诊的21509例≥66岁甲状腺癌患者,中位随访50个月。

主要发现

  • 4168例(19.4%)死于其他原因,2644例(12.3%)死于甲状腺癌。
  • 分化型甲状腺癌患者死于其他原因的可能性超过死于甲状腺癌;未分化癌则相反。
  • 髓样癌患者6.25年后死于其他原因的可能性超过死于甲状腺癌。
  • 男性(HR 1.47;95%CI 1.37-1.57)、黑人种族(HR 1.30;95%CI 1.16-1.46)、心脏病(HR 1.34;95%CI 1.25-1.44)、慢性下呼吸道疾病(HR 1.25;95%CI 1.17-1.34)与死于其他原因相关。
  • 远处SEER分期相比局限期与死于甲状腺癌相关(HR 12.65;95%CI 10.91-14.66)。

临床怎么用

  • 老年甲状腺癌诊疗中应评估合并症等竞争风险,个体化制定管理策略。
  • 研究结果可用于开发考虑竞争性死亡原因的决策模型,辅助临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Understanding the impact of comorbidities and competing risks of death when caring for older adults with thyroid cancer is key for personalized management. The objective of this study was to determine whether older adults with thyroid cancer are more likely to die from thyroid cancer or other etiologies, and determine patient factors associated with each. Methods: The Surveillance, Epidemiology, and End Results (SEER)-Medicare database was used to identify patients aged ≥66 years diagnosed with thyroid cancer (papillary, follicular, Hürthle cell, medullary, anaplastic, and other) between 2000 and 2015 (median follow-up, 50 months). We analyzed time to event (i.e., death from other causes or death from thyroid cancer) using cumulative incidence functions. Competing risk hazards regression was used to determine the association between patient (e.g., age at diagnosis and specific comorbidities) and tumor characteristics (e.g., SEER stage) with two competing mortality outcomes: death from other causes and death from thyroid cancer. Results: Of 21,509 patients with a median age of 72 years (range 66-106), 4168 (19.4%) died of other causes and 2644 (12.3%) died of thyroid cancer during the study period. For differentiated thyroid cancer patients, likelihood of dying from other causes exceeds likelihood of dying from thyroid cancer, whereas the opposite is true for anaplastic thyroid cancer. For medullary thyroid cancer, after 6.25 years patients are more likely to die from other etiologies than thyroid cancer. Using competing risks hazards regression, male sex (hazards ratio [HR] 1.47; 95% confidence interval [CI 1.37-1.57]), black race (HR 1.30; CI [1.16-1.46]), and comorbidities (e.g., heart disease, HR 1.34; CI [1.25-1.44]; chronic lower respiratory disease, HR 1.25; CI [1.17-1.34]) were associated with death from other causes. Tumor characteristics such as histology, tumor size, and stage correlated with death from thyroid cancer (e.g., distant SEER stage compared with localized, HR 12.65; CI [10.91-14.66]). Conclusions: The clinical context, including patients' specific comorbidities, should be considered when diagnosing and managing thyroid cancer. Our findings can be used to develop decision models that account for competing causes of death, as an aid for clinical decision making.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Papaleontiou M, Norton EC, Reyes-Gastelum D, et al. Competing Causes of Death in Older Adults with Thyroid Cancer. Thyroid. 2021. PMID: 33764188. doi:10.1089/thy.2020.0929

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。